

GENERIS

EUROPEAN BIOMANUFACTURING SUMMIT 2026

Fall 2026

biomaneurope.com

TOMORROW'S CONNECTION TODAY

Designing a new future for manufacturing, quality and supply chain leaders

+49 40 74305767
info@generisgp.com

PROGRAMME

PROGRAMME · DAY 1

JOIN US FOR THE PRE-EVENT HAPPY HOUR ON 23 NOVEMBER 2026 FROM 18.00-19.00 CET

24 NOVEMBER 2026

7.00 - 8.00 CET

REGISTRATION AND NETWORKING BREAKFAST

8.00 - 8.10 CET

CHAIR'S WELCOME AND OPENING REMARKS

JON WILLIS
Partner
Chartwell

JONNY SÅGÄNGER
Editor, Pharma Market and Medtech & Digital Health News Services
Bonnier News Business (Sweden)

8.10 - 8.40 CET

KEYNOTE

SARAH DAYRE
SVP, EMEA Supply and Sweden Operations
AstraZeneca

INTEGRATING AUTOMATION TECHNOLOGIES TO IMPROVE END-TO-END SUPPLY CHAIN VISIBILITY AND EFFICIENCY IN BIOMANUFACTURING NETWORKS

- Optimizing planning and inventory management through real-time data integration across distribution systems
- Reducing supply variability and bottlenecks by automating procurement, scheduling, and logistics coordination processes
- Implementing scalable automation solutions that support agile supply chain adaptation across fluctuating demand and production volumes
- Enhancing supply chain reliability by minimizing manual interventions in order processing, tracking, and fulfillment workflows
- Leveraging advanced analytics and AI to improve demand forecasting, capacity planning, and supply risk detection
- Strengthening supplier collaboration through automated data exchange and integrated digital supply chain platforms
- Training teams on supply chain-critical aspects of operating automated systems

8.40 - 9.10 CET

PLENARY

TONGTONG WANG
SVP and Global Head, Pharma Technical Development
Roche

AUGMENTING CMC DEVELOPMENT AND MANUFACTURING WITH SYSTEM DESIGNS, LEADERSHIP, AND ARTIFICIAL INTELLIGENCE

- Building adaptable platform technologies across diverse modalities, combination products, and device delivery systems
- Integrating R&D, clinical, and commercial functions to embed Quality by Design from early molecule design through commercial manufacturing
- Designing responsive operating models that accelerate development and enable faster progression of complex molecules toward NDA, BLA, and MAA submissions
- Advancing regulatory strategies and post-approval change processes through greater collaboration with global regulatory agencies
- Case study: partnering with ValueAddGroup to scale leadership and artificial intelligence with urgency across technical development

9.10 - 9.40 CET

PLENARY

SPEAKER TBA

Hitachi, Ltd.

AUTOMATING HIGH-THROUGHPUT BIOMANUFACTURING FOR QUALITY AND RELIABILITY

- Integrating automated inspection and precision handling into high-throughput pharmaceutical manufacturing environment
- Strengthening real-time quality control through integrated vision systems and automated defect detection
- Connecting production equipment with SCADA and MES platforms to improve manufacturing visibility and traceability
- Reducing manual intervention and process variability across complex assembly and production workflows
- Designing flexible automation platforms that accommodate product variants, changing demand and future production requirements
- Improving equipment availability and manufacturing efficiency while maintaining GMP-compliant production standards

9.45 - 11.25 CET

REFRESHMENTS, NETWORKING, AND PRE-ARRANGED 1-2-1 MEETINGS

11.30 - 11:40 CET

WELCOME ADDRESS

CHRISTIAN ZAUM
Commissioner for Economic Affairs, Law, Order and Health
City of Düsseldorf

11.40 - 12.10 CET

SESSIONS

MANUFACTURING

ULLA GROVE KROGSGAARD THOMSEN, PH.D.
Chief Executive Officer
Novo Nordisk Pharmatech A/S

SCALING STEM CELL THERAPIES: FROM BIOLOGICAL PROMISE TO MANUFACTURING REALITY

- Exploring the evolving demand for stem cell-based therapies and its implications on biomanufacturing capacity and infrastructure
- Addressing critical scale-up bottlenecks in stem cell production, including consistency, quality control, and regulatory compliance
- Leveraging advanced raw materials, enzymes, and process innovations to enable robust and reproducible cell manufacturing
- Designing flexible, scalable manufacturing platforms to support the transition from clinical to commercial-scale regenerative therapies
- Integrating supply chain resilience and strategic capacity expansion to meet rising global demand for advanced therapies
- Driving collaboration across industry partners to accelerate innovation and standardization in next-generation biomanufacturing ecosystems

QUALITY

HIROKI TAKAMATSU
VP and Executive Officer, Quality Division
Kyowa Kirin

DRIVING BIOLOGICS MANUFACTURING EXCELLENCE THROUGH INTEGRATED QUALITY LEADERSHIP

- Ensuring process reliability and reproducibility across upstream cell culture, fermentation, and downstream purification operations
- Embedding quality controls throughout biologics workflows, from raw materials to final drug substance, to minimize deviations and maintain batch consistency
- Coordinating multi-site biomanufacturing operations to ensure uniform product quality and readiness for global regulatory inspections
- Leveraging data-driven monitoring and predictive analytics to proactively detect and prevent process excursions in complex biologics systems
- Integrating tech transfer and scale-up activities with rigorous quality oversight to support seamless production of clinical and commercial biologics
- Fostering a culture of quality in biomanufacturing, empowering teams to uphold regulatory standards while driving operational efficiency

12.15 - 12.45 CET

WORKSHOP

ROOM 1

FRANK VELTE, PH.D.
Head, Pharma and Biotech
CG PHARMA & BIOTECH

BUFFER PREPARATION IN BIOPHARMA: FROM BOTTLENECK TO STRATEGIC OUTSOURCING – MAKE OR BUY

- Role of buffers in mAb downstream
- Example: buffer consumption by unit operation
- Technical challenges across the process chain
- Cleaning-in-place (CIP) and changeovers
- Make-or-buy decision framework
- Outsourcing models and enabling technologies

ROOM 2

MATHIEU FLECHELLE
Director, Supply Chain and Procurement
FinVector

FREDERIK JAENEN
VP, Sales for Binocs Technology
Bluecrux

FINVECTOR'S JOURNEY TOWARDS INTEGRATING SUPPLY CHAIN & QC PLANNING

- Exploring FinVector's journey towards positioning Quality Control as an active partner in end-to-end supply chain planning
- Identifying how QC bottlenecks and waiting times contribute to extended batch lead times and inventory build-up
- Aligning QC and Supply Chain teams on short-term execution and mid-term capacity planning
- Integrating QC capacity and timelines into supply chain planning and decision-making
- Connecting systems and data to enable continuous coordination beyond periodic planning meetings
- Examining the potential of AI agents to support integrated QC and Supply Chain planning

12.50 - 13.50 CET

LUNCH AND LEARN ROUNDTABLES

NICOLE WELLENS
Director, Bioprocessing, Europe
Lonza

KELLY MOLDER
Senior Subject Matter Expert, Bioprocessing Sales, EMEA
Lonza

WHAT SLOWS SCALE-UP? HIDDEN BOTTLENECKS FROM PROCESS DEVELOPMENT TO COMMERCIAL MANUFACTURING

FRANCESCO CURCIO, MD
Chief Executive Officer and Chief Scientific Officer
VivaBioCell

SCALING CELL THERAPY MANUFACTURING FROM MANUAL PROCESSES TO AUTOMATED, CLOSED-SYSTEM PRODUCTION

SPEAKER TBA

Hitachi, Ltd.

LEVERAGING PRACTICAL AUTOMATION STRATEGIES FOR SMARTER BIOMANUFACTURING OPERATIONS

13.55 - 14.25 CET

SESSIONS

MANUFACTURING

FABRICE ETIENNE
VP, Vector and External Manufacturing Operations
Bristol Myers Squibb

INTEGRATING VECTOR AND CELL MANUFACTURING OPERATIONS TO SCALE ADVANCED THERAPIES

- Aligning make-to-stock vector manufacturing and make-to-order cell processing around a single patient demand signal
- Building integrated planning and inventory strategies that balance supply reliability with patient scheduling needs
- Managing operational complexity across vector production, cell processing, and external manufacturing networks through unified governance
- Scaling advanced therapies by synchronizing capacity expansion, supply planning, and manufacturing readiness across two distinct operating models
- Establishing performance metrics and decision frameworks that connect upstream manufacturing activities to downstream patient impact
- Developing the cross-functional capabilities, partnerships, and systems thinking required to manage end-to-end cell therapy supply chains at scale

QUALITY

FABIO RONCORONI
Site Head, Basel Drug Substance
Roche

STRENGTHENING DRUG SUBSTANCE MANUFACTURING PERFORMANCE THROUGH SITE-LEVEL OPERATIONAL EXCELLENCE

- Optimising drug substance operations around capacity, reliability, quality, and cost performance
- Balancing production flexibility with increasingly complex manufacturing and supply requirements
- Strengthening process robustness and operational resilience across critical manufacturing activities
- Embedding data-driven decision-making to improve visibility, responsiveness, and day-to-day site performance
- Developing manufacturing capabilities and ways of working that enable continuous improvement at scale
- Aligning people, processes, technology, and quality expectations to build a high-performing drug substance site

14.30 - 15.00 CET

WORKSHOPS

ROOM 1

KELLY MADDISON
Sales Solution Engineer
Sapio Sciences

CLOSING THE GAP: CONNECTING QC AND BIOANALYTICAL DATA ACROSS BIOMANUFACTURING

- Bridging R&D, process development, QC, and manufacturing with a connected digital thread
- Connecting QC LIMS with bioanalytical and process (BioA/P) data to reduce silos and rework
- Standardizing workflows across ELN, LIMS, and scientific data management
- Improving data integrity, traceability, and cross-functional collaboration
- Accelerating technology transfer from development to manufacturing
- Enabling AI-ready, regulatory-compliant biomanufacturing at scale

ROOM 2

TIZIAN BUCHER, PH.D
Head, R&D
DrM Group

INCREASING EFFICIENCY AND REDUCING RISK IN BIOPROCESSING WITH INNOVATIVE SU FILTERS AND MIXERS

- Presenting cyclical cake filtration as an efficient microcarrier separation and primary harvesting technique
- Demonstrating how innovative filtration can increase processing efficiency while reducing associated process risks
- Introducing vibratory mixers and contrasting their capabilities with traditional stirred-tank systems for fill/finish and challenging mixing applications
- Exploring how robust mixer construction and a wide application range support processing from shear-sensitive liquids to ultra-high particle loadings
- Highlighting the relevance of both technologies across key bioprocessing applications, including cell and gene therapy, mAb production and fill/finish
- Sharing real-world biopharma case studies across upstream and downstream processing to draw actionable lessons on performance, process risk and cost

15.05 – 16.25 CET

HAPPY HOUR AND PRE-ARRANGED 1-2-1 BUSINESS MEETINGS

16.30 - 17.00 CET

PLENARY

KELLY MOLDER
Senior Subject Matter Expert, Bioprocessing Sales, EMEA
Lonza

SIMPLIFYING CUSTOM MEDIA FROM DEVELOPMENT TO GMP WITH AN END-TO-END APPROACH

- Key considerations and risks when outsourcing custom cell culture media
- Accelerated CHO media screening and optimization through Lonza's Media Development Lab (MDL)
- Rapid Media Prototyping (RaMP) for non-GMP liquid and powder media production
- End-to-end custom media solutions, from development and technology transfer to GMP manufacturing

17.00 - 17.45 CET

PANEL DISCUSSION

MAUREEN LARKIN
Executive Director and Site Lead, College Park
Alexion

HANS-PETER GRAU
SVP and Head, Global Biotech Manufacturing
Merck KGaA

MARCIA BLACKMOORE
Chief Commercial Officer and Customer Operations
L7 Informatics, Inc.

BHUSHAN DESAI
AVP, Manufacturing Operations and Site Head, Alzey Manufacturing
Eli Lilly

LAETITIA MALPHETTES
Head, Drug Substance Process Sciences
UCB

CRINA BALOG
Senior Director, Large Molecules Drug Substance, MSAT
Johnson & Johnson Innovative Medicine

FROM INNOVATION TO EXECUTION: ENABLING SCALABLE, AGILE AND TECHNOLOGY-FORWARD BIOMANUFACTURING

- Involving manufacturing teams early in development to anticipate scale-up challenges and ensure production capabilities keep pace with innovation
- Increasing manufacturing speed and flexibility through shorter production campaigns, smaller batches and higher-yielding processes
- Integrating AI, digital twins and MES while addressing data readiness, regulatory expectations and increasingly data-driven inspections
- Strengthening collaboration between development, manufacturing and technology teams to improve technology transfer and commercial-scale process performance
- Combining targeted recruitment with upskilling to build teams with the scientific and digital expertise needed for modern biomanufacturing
- Managing growing process complexity and faster development timelines without compromising quality, compliance or risk management

17.45 - 17.55 CET

CHAIR'S CLOSING REMARKS

MANUFACTURING

JON WILLIS
Partner
Chartwell

QUALITY

JONNY SÅGÄNGER
Editor, Pharma Market and Medtech & Digital Health News Services
Bonnier News Business (Sweden)

17.55 - 18.55 CET

NETWORKING DRINKS RECEPTION

PROGRAMME · DAY 2

25 NOVEMBER 2026

7.00 - 8.00 CET

REGISTRATION AND NETWORKING BREAKFAST

8.00 - 8.10 CET

CHAIR'S WELCOME AND OPENING REMARKS

MANUFACTURING

JON WILLIS
Partner
Chartwell

QUALITY

JONNY SÅGÄNGER
Editor, Pharma Market and Medtech & Digital Health News Services
Bonnier News Business (Sweden)

8.10 - 8.40 CET

KEYNOTE

FERHAT ZATSAN
SVP, Operations
Ceva

REVOLUTIONIZING CELL THERAPY SUPPLY CHAINS FOR SCALABLE MANUFACTURING SUCCESS

- Building flexible manufacturing networks capable of supporting commercial-scale cell therapy demand across global markets
- Using automation and digital orchestration tools to improve coordination between manufacturing sites, logistics providers, and clinical partners
- Maintaining product integrity during transport by strengthening cold chain infrastructure and real-time shipment monitoring
- Navigating the operational complexity of vein-to-vein delivery while reducing turnaround times for patient-specific therapies
- Creating stronger partnerships with suppliers to improve material availability, traceability, and long-term supply continuity
- Balancing rapid innovation with evolving regulatory expectations surrounding handling, distribution, and chain-of-identity requirements

8.40 - 9.10 CET

PLENARY

BIRK VANDERWEEËN
SVP, Global Manufacturing and Supply
Legend Biotech

SCALING GLOBAL CELL THERAPY MANUFACTURING FOR RELIABLE PATIENT ACCESS

- Designing global manufacturing footprints capable of supporting autologous and advanced therapy production
- Strengthening process robustness to reduce turnaround times and manufacturing variability
- Coordinating multi-site operations to ensure consistency and inspection readiness
- Balancing capacity expansion with quality and regulatory expectations
- Preparing the network for clinical and commercial readiness for the In Vivo platform
- Automation and digital Innovation as key enablers for competitiveness in cell therapies

9.15 - 9.45 CET

WORKSHOP

ROOM 1

MICHAEL JUUL JENSEN
Manager, Global Sales and Process Technology
Sani Membranes A/S

ENHANCING MF/UF APPLICATIONS THROUGH DYNAMIC VIBRO® MEMBRANE FILTRATION (VMF)

- Vibro® Membrane Filtration (VMF) is an advanced membrane filtration system for biotech, pharmaceutical, food, and industrial applications developed and manufactured by Sani Membranes A/S
- Minimizing fouling and maintaining stable filtration performance using targeted vibrations on the membrane surface
- Enabling higher yields, improved product recovery, and enhanced separation efficiency compared to conventional crossflow filtration methods
- Effectively addressing challenging filtration streams containing proteins, cells, particles, and high-viscosity products
- Combining innovative membrane technology, application expertise, and full process support from laboratory testing to commercial production

ROOM 2

ANSHUL AGARWAL
Principal
ZS

NIKHIL GUPTA
Manager, Strategy Insights and Planning
ZS

REIMAGINING BIOMANUFACTURING WORKFLOWS WITH AGENTIC AI

- Redesigning biomanufacturing workflows with our agentic process execution solution
- Applying AI-enabled process mining to uncover inefficiencies and decision bottlenecks
- Automating redesigned processes through human-in-the-loop agents that can be rapidly configured using low-code/no-code tools
- Enabling adaptive control, higher yield and compliance by design
- Transforming use cases such as intelligent batch release, NC/CAPA management, complaint management, batch genealogy etc.

9.50 - 11.10 CET

REFRESHMENTS, NETWORKING, AND PRE-ARRANGED 1-2-1 MEETINGS

11.15 - 11.45 CET

SESSIONS

MANUFACTURING

WENSHI WANG
Chief Technology Officer
Darwin Biotech

MANAGING CHANGE CONTROL STRATEGIES FOR COMMERCIAL CELL AND GENE THERAPY MANUFACTURING

- Evaluating the impact of manufacturing process changes on product comparability and clinical performance
- Implementing structured change control frameworks to support lifecycle management of commercial CGT products
- Aligning process development, manufacturing, and quality teams to assess and document critical changes
- Maintaining product consistency when introducing new technologies equipment or process improvements
- Navigating regulatory expectations for post-approval manufacturing changes across global markets
- Strengthening risk assessment strategies to ensure patient safety while enabling operational flexibility

QUALITY

OLIVER JOHN NIGGE, PH.D.
Senior Director, RDQA Audit and Supplier Quality
AbbVie

IMPLEMENTING CGMPS TO ENHANCE BIOMANUFACTURING COMPLIANCE AND QUALITY

- Understanding the latest updates to cGMP regulations and their impact on biomanufacturing practices
- Ensuring continuous training and education for staff to maintain cGMP compliance
- Developing robust documentation practices to meet cGMP requirements and improve traceability
- Integrating quality management systems with cGMP to streamline operations and reduce errors
- Auditing manufacturing facilities to identify gaps and implement corrective actions for cGMP compliance
- Collaborating with regulatory bodies to stay ahead of compliance challenges in biomanufacturing

11.50 - 12.20 CET

SESSIONS

MANUFACTURING

DAVID OCHSENBEIN
Senior Director, Process Science Modeling and Data
Johnson & Johnson

DIGITALIZING PHARMACEUTICAL MANUFACTURING: A DECADE OF PROGRESS AND LESSONS LEARNED AT J&J

- Patient needs guide digital investment: Improving supply reliability and shorten the time needed to deliver medicines
- Digital models/shadows/twins improve manufacturing: Accelerating technology transfers, detect process drift and help prevent batch failures
- Real-time release changes quality assurance: Using validated process measurements and predictive models to reduce reliance on laboratory testing and shorten release timelines
- Advanced control expands manufacturing automation: Connecting real-time process insights with control strategies to improve manufacturing robustness and reliability
- Agentic AI broadens access to process expertise: Connecting trusted data and models to support investigations and progress toward governed, increasingly autonomous manufacturing
- Scaling requires more than technology: Building teams close to manufacturing, simplify solutions and combine strong data foundations with GMP risk awareness

QUALITY

SILVIA ANDREI
Director, Quality, Affiliates and Distributor Markets
Amicus Therapeutics

BRIDGING THE GAP BETWEEN MANUFACTURING AND MARKET READINESS FOR RARE DISEASE THERAPIES

- Addressing the critical transition between manufacturing completion and commercial market readiness for rare disease therapies
- Navigating quality and regulatory requirements beyond the manufacturing environment to enable successful product launches
- Coordinating Quality, Regulatory Affairs, Supply Chain and Commercial teams to close gaps in launch preparation
- Establishing GDP-compliant distribution networks and qualified partners across European affiliate and distributor markets
- Identifying overlooked risks in product release, distribution and market authorisation that can delay patient access
- Strengthening end-to-end quality oversight to ensure a seamless transition from manufacturing operations to commercial distribution

12.25 - 13.25 CET

LUNCH AND LEARN ROUNDTABLES

JULIA WIESNER
Site Head, Technical Operations
Merz

IMPROVING STERILE DRUG PRODUCTION WITH AUTOMATED VISUAL INSPECTION

VENKI ANANTHARAM
Head, Digital, Global Quality
Amgen

TRANSFORMING GLOBAL QUALITY THROUGH DIGITAL SYSTEMS AND DATA-DRIVEN COMPLIANCE

GRAHAM MCCARTNEY
Director, European Manufacturing Operations
Samsung Bioepis

INSIGHTS INTO BIOPROCESS PLATFORM EVOLUTION

DARREN O'BRIEN
Head, Technology
Amgen

SCALING NEXT GENERATION BIOMANUFACTURING FACILITIES FOR GLOBAL GROWTH

CRINA BALOG
Senior Director, Large Molecules Drug Substance, MSAT
Johnson & Johnson Innovative Medicine

DO WE STILL NEED TRADITIONAL PPQ? RETHINKING PROCESS VALIDATION, VERIFICATION AND SCALE-UP

MIREILLE SANDERS
Chief Operations Officer
Pharming Group

EXTERNAL MANUFACTURING FOR RARE DISEASE PRODUCTS: BUILDING RESILIENT, PATIENT-CENTRIC SUPPLY MODELS AMID SUPPLY CONSTRAINTS

SRIDHAR BALASUBRAMANIAN
Head, Quality Steriles, Global Audit and Compliance
Dr. Reddy's

MAXIMIZING STERILITY WITH ADVANCED ASEPTIC FILL AND FINISH PROCESSES

13.30 - 14.15 CET

PANEL DISCUSSION

TONGTONG WANG
SVP and Global Head, Technical Development
Roche

JULIA WIESNER
Site Head, Technical Operations
Merz

ULLA GROVE KROGSGAARD THOMSEN, PH.D.
Chief Executive Officer
Novo Nordisk Pharmatech A/S

MIREILLE SANDERS
Chief Operations Officer
Pharming Group

LAETITIA MALPHETTES
Head, Drug Substance Process Sciences
UCB

WOMEN IN LEADERSHIP: BUILDING INCLUSIVE, HIGH-IMPACT LEADERSHIP IN BIOMANUFACTURING

- Defining leadership success through business impact, credibility, and the ability to create meaningful change
- Sharing career experiences from technical, scientific, and operational environments and the experiences that shaped leadership approaches
- Exploring how mentorship, sponsorship, and career development can create greater visibility and opportunities for emerging leaders
- Building inclusive teams by challenging assumptions, broadening perspectives, and ensuring diverse voices contribute to key decisions
- Strengthening leadership pipelines through talent development, succession planning, and practical approaches to supporting high-potential colleagues
- Examining how organisations can create environments where different backgrounds, experiences, and leadership styles can contribute to long-term performance

14.15 - 14.45 CET

SESSIONS

WELHA ZIRI
VP and General Manager, Dunkirk
AstraZeneca

PERFORMANCE BEFORE TECHNOLOGY: HOW ASTRAZENECA DUNKIRK BUILT THE FOUNDATIONS FOR SUSTAINABLE DIGITAL PERFORMANCE

- Accelerating throughput by vertically ramping manufacturing assets
- Implementing cutting-edge technologies to optimise line performance
- Integrating new projects quickly into existing production lines
- Empowering teams to leverage tools and skills for faster operations
- Enhancing process monitoring to reduce variability and maximise output
- Driving continuous improvement by combining technology, people, and scalable workflows

14.45 - 15.30 CET

PANEL DISCUSSION

LIESBETH FOESTERS
VP and Head, External and Clinical Supply Quality
UCB

VENKI ANANTHARAM
Head, Digital, Global Quality
Amgen

BIRK VANDERWEEËN
SVP, Global Manufacturing and Supply
Legend Biotech

OLIVER JOHN NIGGE, PH.D.
Senior Director, RDQA Audit and Supplier Quality
AbbVie

JONNY SÅGÄNGER
Editor, Pharma Market and Medtech & Digital Health News Services
Bonnier News Business (Sweden)

BEHNAM HEIDARI, PH.D.
Head, Global IBP and Performance, General Medicine
Sanofi

DEVELOPING THE SKILLS AND LEADERSHIP TO NAVIGATE BIOMANUFACTURING CHANGE

- Identifying the capabilities that matter most as biomanufacturing requirements evolve
- Upskilling existing employees through targeted training, career progression, and continuous learning
- Preparing emerging leaders for the realities of complex leadership roles
- Equipping leaders to guide teams through acquisitions, reorganizations, and ongoing organizational change
- Strengthening employee engagement and retention through meaningful career opportunities
- Navigating generational differences in career expectations, ambition, and approaches to work

15.30 - 15.40 CET

CHAIR'S CLOSING REMARKS

MANUFACTURING

JON WILLIS
Partner
Chartwell

QUALITY

JONNY SÅGÄNGER
Editor, Pharma Market and Medtech & Digital Health News Services
Bonnier News Business (Sweden)